UK markets close in 1 hour 27 minutes
  • FTSE 100

    7,517.75
    +146.29 (+1.98%)
     
  • FTSE 250

    21,965.67
    +319.96 (+1.48%)
     
  • AIM

    1,097.77
    +13.56 (+1.25%)
     
  • GBP/EUR

    1.1964
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.3500
    -0.0006 (-0.04%)
     
  • BTC-GBP

    28,334.63
    +1,286.66 (+4.76%)
     
  • CMC Crypto 200

    880.97
    +25.16 (+2.94%)
     
  • S&P 500

    4,441.80
    +85.35 (+1.96%)
     
  • DOW

    34,793.98
    +496.25 (+1.45%)
     
  • CRUDE OIL

    87.09
    +1.49 (+1.74%)
     
  • GOLD FUTURES

    1,833.70
    -18.80 (-1.01%)
     
  • NIKKEI 225

    27,011.33
    -120.01 (-0.44%)
     
  • HANG SENG

    24,289.90
    +46.29 (+0.19%)
     
  • DAX

    15,485.83
    +361.96 (+2.39%)
     
  • CAC 40

    7,008.07
    +170.11 (+2.49%)
     

ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • OBSV

GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Monday, January 10, 2022.

A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website, starting Friday, January 14, 2022.

About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com

For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting